Navigation Links
Rare Blood Vessel Disease Could Have New Treatment Option
Date:7/14/2010

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, July 14 (HealthDay News) -- A drug already used to treat lymphoma and rheumatoid arthritis shows promise as an option to treat rare forms of vasculitis, a disease affecting the blood vessels, according to two new studies.

The drug, rituximab, appeared to be as effective as the current standard, cyclophosphamide, in treating antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Rituximab may even be superior to cyclophosphamide in treating disease recurrences, the researchers found.

This is the first time in 40 years that a new drug has emerged to treat these conditions, according to the authors of the studies, both appearing in the July 15 issue of the New England Journal of Medicine.

"This trial has demonstrated for the first time there is an effective alternative to cyclophosphamide for remission induction, and there are a variety of results that make us think that rituximab should be the treatment of choice for remission induction," said Dr. John H. Stone, director of clinical rheumatology at Massachusetts General Hospital in Boston, referring to one of the studies, of which he was first author.

"I think these are two very important pivotal studies that bring hope to patients with ANCA vasculitis. And despite the fact that they are relatively small studies, they are proof of principle that this medicine has the ability to get rid of the group of cells that produce the [antibody]," added Dr. Ronald J. Falk, director of the University of North Carolina Kidney Center at Chapel Hill, and author of an accompanying editorial. "These antibodies are actually causing the disease, so by getting rid of them, one is really now attacking the disease cause rather than just disease symptoms."

"ANCA-associated vasculitis consists of two primary diseases, Wegener's granulomatosis and microscopic polyangitis," explained Stone.

The con
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Inflammatory Bowel Ups Risk for Blood Clots
2. Bowel disease link to blood clots
3. Local Blood Supply Impacted by Wednesdays Severe Snow Storm
4. PERSONALABS Offers Discounted Healthy Heart Online Blood Tests in February
5. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
6. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
7. Bilberry Seems to Act Against Blood Sugar
8. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
9. UCR researcher identifies mechanism malaria parasite uses to spread in red blood cells
10. NHLBI, CDC launch surveillance and research program for inherited blood diseases
11. IOM report declares high blood pressure a neglected disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rare Blood Vessel Disease Could Have New Treatment Option
(Date:7/11/2014)... 11, 2014 Riverside Health System became the ... in Virginia in late 2012 and now, in partnership with ... residents throughout the Williamsburg and Newport News region. , Also ... and benefits to independent older adults who wish to remain ... safety net of continuing care services as well as control ...
(Date:7/11/2014)... Europe is one of the largest consumers of micro ... area. The agricultural sector is a significant user of ... the total water use. The scale and importance of ... far from negligible in most northern ones. , In ... the water use in most countries, while in the ...
(Date:7/11/2014)... July 11, 2014 Pigments are insoluble ... mainly three functions namely protective coating, opacity, and coloring. ... materials that impart color to substances such as paper, ... the pigments, which upon application impart color to the ... oxide, carbon black, and hematite. , The coloring action ...
(Date:7/11/2014)... the best available treatment for patients, from a range ... for taxpayers than the existing clinical trial process, a ... carried out while he was a member of the ... based at The University of Manchester,s Health eResearch Centre, ... ) today (Friday 11 July) looked at the use ...
(Date:7/11/2014)... Mexico (PRWEB) July 11, 2014 Experience ... the Mayan Heritage Experience Package at the luxury all-inclusive ... the package include a guided on-site ecological family tour ... well as The Coba Mayan Encounter Tour at the ... Nohoch Muul, the tallest pyramid in the Yucatan and ...
Breaking Medicine News(10 mins):Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3Health News:Better use of electronic health records makes clinical trials less expensive 2Health News:Explore the Aura and Mystery of the Yucatan’s Mayan Culture with New Hotel Package at AAA Five Diamond Grand Velas Riviera Maya 2Health News:Explore the Aura and Mystery of the Yucatan’s Mayan Culture with New Hotel Package at AAA Five Diamond Grand Velas Riviera Maya 3
... , SHENZHEN, China, Dec. 22 /PRNewswire-FirstCall/ - Hard to ... that it has an agreement in principle to sell its ... in China. The buyer, founded in 2004, focuses on production ... Name of the buyer will be announced in a joint ...
... lifestyle on top of genetics , TUESDAY, Dec. 22 (HealthDay ... take an additional toll on sun-damaged skin, a new study ... Western Reserve Medical School in Cleveland, suggest that "people with ... same sort of sun damage," said Dr. Jonette Keri, an ...
... the University of Central Florida have found a protein that ... common and aggressive brain tumors in adults. Glioblastoma multiforme ... late U.S. Sen. Edward Kennedy, is difficult to treat because ... very quickly. About 10,000 cases are diagnosed in the United ...
... the hemophilia mutation that affected Queen Victoria and her European ... Able to trace rare genetic disease mutations, the tool can ... Now, Tel Aviv University has its own deep sequencer ... Analyzer housed in a new Genome Facility. The tool ...
... in Canada are reporting the development of a fast, ... that may exist in foods and beverages. Their paper-strip ... results in minutes rather than hours by means of ... published in ACS, Analytical Chemistry , a semi-monthly ...
... , , ATLANTA, Dec. ... the market leader in automated revenue integrity solutions that improve ... the rank of first in the Revenue Cycle - Chargemaster ... KLAS Awards: Software & Professional Services" report, published December 2009. ...
Cached Medicine News:Health News:Hard to treat Diseases (HTDS) To Sell Its MindUp BioResearch Division 2Health News:Hard to treat Diseases (HTDS) To Sell Its MindUp BioResearch Division 3Health News:Hard to treat Diseases (HTDS) To Sell Its MindUp BioResearch Division 4Health News:Sun, Smoke, Extra Weight Add Years to Skin 2Health News:Sun, Smoke, Extra Weight Add Years to Skin 3Health News:Adding a genetic supertool 2Health News:Craneware's Chargemaster Toolkit(R) Earns #1 KLAS Rank for Fourth Consecutive Year 2Health News:Craneware's Chargemaster Toolkit(R) Earns #1 KLAS Rank for Fourth Consecutive Year 3
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
(Date:7/10/2014)... WOONSOCKET, R.I. , July 10, 2014 CVS ... its board of directors has approved a quarterly dividend of ... The dividend is payable on August 1, 2014, to holders ... Caremark CVS Caremark is dedicated to helping ... integrated pharmacy company in the United States ...
(Date:1/15/2014)... 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting ... China,s orthopedic instrument industry has ... size rising from 3.28 billion yuan in 2006 to ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3
... , REDWOOD CITY, Calif., July 22 ... the full results of the PAS-Port system multi-center pivotal trial, known ... the peer-reviewed publication The J ournal of Thoracic and ... from the U.S. Food and Drug Administration (FDA) in September 2008, ...
... , , SOUTH SAN FRANCISCO, ... ), a biopharmaceutical company focused on innovative oncology therapies, today announced ... new generation platinum-based chemotherapy agent and the Company,s lead product candidate. ... (FDA) to design this study, which is required for new chemical ...
Cached Medicine Technology:Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results 2Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results 3Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results 4Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing 2Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: